CD8A and neoplasm: TIL-CD20+ B have been found close to CD8+ T cells, and the presence of both CD20+ and CD8+ lymphocytes has been associated with longer survival especially in ovarian cancer, compared with patients affected by a tumor lacking B cells [84].